Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.

Abstract

Tofacitinib is a pan-janus kinase inhibitor (JAK) which has been tested off-label in alopecia areata (AA) with promising results. However, evidence of tofacitinib in real-life setting is still poor. We evaluated long-term efficacy and safety of tofacitinib for refractory AA. This is a prospective, open-label, observational, single-center cohort study conducted between January 2018 and December 2020. Primary end-point was the percent change in Severity of Alopecia Tool (SALT) at the basal visit and at the most recent follow-up visit. Three categories of treatment response were analyzed. Data on 47 participants of Arab-Asian heritage were analyzed. A complete and partial regrowth was observed in 18 patients (41.86%) and 11 patients (25.58%), respectively. In 12 patients (27.9%), no response was obtained. Most of the non-responders belonged to the alopecia universalis group (66.67%). No statistical differences were observed in rates of regrowth between pediatric and adult individuals (p = 0.52), nor between women and men. Significant differences in the average duration of tofacitinib treatment were obtained among the three categories of regrowth (p < 0.003), notably duration of AA did not impact the clinical regrowth (p = 0.62). To the best of our knowledge, this is the first prospective, observational, long-term study using tofacitinib in refractory AA. Rates of regrowth and side effects are analogous to previous works. Length of tofacinitib therapy should last for 12 months before considering any discontinuation or change, since early cessation can lead to treatment failures or incomplete regrowth. Maintenance therapy after complete regrowth has demonstrated to be safe and effective to prevent recurrences of hair loss.

• Authors: Husein Husein-ElAhmed, Nada Abdulla, Amina Al-Obaidli, Majid Ali-Alam, Martin Steinhoff
• Journal: Dermatologic therapy (Dermatol Ther) Vol. 35 Issue 12 Pg. e15871 (12 2022) ISSN: 1529-8019 [Electronic] United States
• PMID: 36177791 (Publication Type: Observational Study, Journal Article)
• Copyright: © 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.

Chemical References

• tofacitinib
• Pyrroles

Topics

• Adult
• Male
• Humans
• Female
• Child
• Alopecia Areata (diagnosis, drug therapy, chemically induced)
• Prospective Studies
• Arabs
• Cohort Studies
• Pyrroles (adverse effects)
• Alopecia (diagnosis, drug therapy, chemically induced)